Literature DB >> 32416587

Idiopathic pulmonary fibrosis: Significance of the usual interstitial pneumonia (UIP) CT-scan patterns defined in new international guidelines.

T Diridollou1, L Sohier2, C Rousseau3, A Angibaud4, P Chauvin4, T Gaignon4, M Tas5, J Lemerre5, M Kerjouan4, A Salé4, M Lederlin5, S Jouneau6.   

Abstract

INTRODUCTION: The new 2018 international guidelines for diagnosing usual interstitial pneumonia (UIP)/idiopathic pulmonary fibrosis (IPF) by CT scan split the old pattern possible UIP (2011 IPF guidelines) into two new patterns: probable UIP and indeterminate for UIP. However, the proportions and prognoses of these new CT-scan patterns are not clear.
METHODS: We used a monocentric retrospective cohort of 322 patients suspected of having IPF (University Hospital of Rennes; Competence Center for Rare Lung Diseases; 1 January 2012-31 December 2017). All patients initially diagnosed by CT scan as possible UIP were included. The chest CT-scans were then reclassified according to the new 2018 international guidelines by 3 observers. These data were then subjected to survival analysis with multivariate Cox regression using a composite endpoint of death, lung transplantation, a decline of≥10% in forced vital capacity (FVC), or hospitalization.
RESULTS: Of the 89 possible UIP patients included, 74 (83%) were reclassified as probable UIP and 15 (17%) as indeterminate for UIP. Probable UIP patients were more likely to meet the composite endpoint (56/74 [75.7%] vs. 5/15 [33%] patients; HR [IC 95%] =3.12 [1.24; 7.83], P=0.015). Multivariate analysis indicated that the probable UIP pattern was associated with significantly increased risk of reaching the composite endpoint (HR [95% CI]=2.85[1.00; 8.10], P=0.049).
CONCLUSION: The majority of possible UIP diagnoses corresponded to probable UIP, which was associated with a significantly worse prognosis than indeterminate for UIP. This distinction between these two CT patterns emphasizes the relevance of the new international guidelines for the diagnosis of IPF.
Copyright © 2020 SPLF and Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Computed tomography; Interstitial lung disease; Outcomes; Pirfenidone; Prognostic factors; nintedanib

Mesh:

Substances:

Year:  2020        PMID: 32416587     DOI: 10.1016/j.resmer.2020.02.004

Source DB:  PubMed          Journal:  Respir Med Res        ISSN: 2590-0412


  5 in total

1.  Mosaic attenuation in non-fibrotic areas as a predictor of non-usual interstitial pneumonia pathologic diagnosis.

Authors:  Ignacio Gayá García-Manso; Juan Arenas-Jiménez; Raquel García-Sevila; Sandra Ruiz-Alcaraz; Marina Sirera-Matilla; Elena García-Garrigós; María Ángeles Martínez-García; Luis Hernández-Blasco
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.996

2.  Endogenous Long Pentraxin 3 Exerts a Protective Role in a Murine Model of Pulmonary Fibrosis.

Authors:  Federica Maccarinelli; Mattia Bugatti; Ander Churruca Schuind; Sara Ganzerla; William Vermi; Marco Presta; Roberto Ronca
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

3.  Monocyte and neutrophil levels are potentially linked to progression to IPF for patients with indeterminate UIP CT pattern.

Authors:  Andrew Achaiah; Amila Rathnapala; Andrea Pereira; Harriet Bothwell; Kritica Dwivedi; Rosie Barker; Rachel Benamore; Rachel K Hoyles; Valentina Iotchkova; Ling-Pei Ho
Journal:  BMJ Open Respir Res       Date:  2021-11

Review 4.  Management of musculoskeletal pain in patients with idiopathic pulmonary fibrosis: a review.

Authors:  Svetlana Kašiković Lečić; Jovan Javorac; Dejan Živanović; Aleksandra Lovrenski; Dragana Tegeltija; Jelena Zvekić Svorcan; Jadranka Maksimović
Journal:  Ups J Med Sci       Date:  2022-07-11       Impact factor: 2.646

Review 5.  The pathogenicity of COVID-19 and the role of pentraxin-3: An updated review study.

Authors:  Ria Margiana; Satish Kumar Sharma; Bilal Irshad Khan; Ameer A Alameri; Maria Jade Catalan Opulencia; Ali Thaeer Hammid; Thulfeqar Ahmed Hamza; Sharaf Khamrakulovich Babakulov; Walid Kamal Abdelbasset; Zanko Hassan Jawhar
Journal:  Pathol Res Pract       Date:  2022-09-15       Impact factor: 3.309

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.